All In Biotech

Drug Trial Radar · NCT05774756

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients With Acquired Hypothalamic Obesity

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 143 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

143

Actual

Start

Apr 26, 2023

Primary completion

Mar 18, 2025

Study completion Apr 16, 2027

Sponsor

Lead sponsor
Rhythm Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this trial is to learn how well Setmelanotide works to improve weight reduction, hunger, and quality of life in patients 4 years of age and older with acquired Hypothalamic Obesity (HO). To determine how well setmelanotide works and how safe it is, patients with HO will take a daily injection of either setmelanotide or placebo and complete trial assessments for 52 weeks on a therapeutic regimen. A separate sub-study in patients with congenital HO is detailed under NCT06760546.

Conditions

  • Hypothalamic Obesity

Interventions

  • SetmelanotideDrug

    Solution for daily subcutaneous injection

  • PlaceboDrug

    Placebo matched to setmelanotide for daily subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic RegimenTime frame: Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • UAN Pediatric Endocrinology

    Birmingham, Alabama

  • Rady Children's Hospital

    San Diego, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • University of Florida

    Gainesville, Florida

  • Ann and Robert H. Lurie Children's Hospital

    Chicago, Illinois

  • University of Iowa Stead Family Department of Pediatrics

    Iowa City, Iowa

  • Boston Children's Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Children's Minnesota

    Saint Paul, Minnesota

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Ohio State Wexner Medical Center

    Columbus, Ohio

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Vanderbilt University School of Medicine

    Nashville, Tennessee

  • Seattle Children's Hospital, Research and Foundation - Center for Integrative Brain Research

    Seattle, Washington

  • Hospital for Sick Children

    Toronto, Ontario, Canada

  • Universitaetsklinikum Hamburg-Eppendorf (UKE) - Ambulanzzentrum des UKE GmbH

    Hamburg, Germany

  • Medicover Neuroendokrinologie

    München, Germany

  • University Children's Hospital, Klinikum Oldenburg

    Oldenburg, Germany

  • Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin

    Ulm, Germany

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • Nagano Children's Hospital

    Azumino, Nagano, Japan

  • Toranomon Hospital

    Minato, Tokyo, Japan

  • Prinses Maxima Center for Pediatric Oncology

    Utrecht, Netherlands

  • Birmingham Women and Children's Hospital NHS Trust

    Birmingham, United Kingdom

  • Hull University Teaching Hospital

    Hull, United Kingdom

  • UCL Great Ormond Street Institute of Child Health

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.